Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...

Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children ...

Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...

Bonn-Miller, Ph.D., chief scientific officer at ... who passed away in 2020 due to Dravet syndrome, but whose life was transformed by the magic of a delicate balance of cannabinoids.

Dravet syndrome is a severe genetic disorder marked by frequent, severe seizures and cognitive and behavioral impairments, with an estimated 38,000 affected individuals in the U.S., UK, EU-4, and ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...